iCMLf Forum 2017: Perspectives on Molecular Monitoring for CML: A global perspective

Topics include; molecular monitoring for best patient outcomes, milestone molecular responses in the first 12 months, ELN recommends repeat testing before changing therapy, trend of decline is an important prognostic factor, long-term molecular monitoring is recommended, a rise in a long term optimal responder may indicate non-adherence, frequent monitoring is associated with better adherence on TKI therapy and decreased risk of progression.